In thyroid cancer cells, rebound of ERK signaling upon BRAFV600E treatment may be caused by downregualtion of ERK phosphatase DUSP5 and increased HER3 expression [12]. This evidence concerns the gene DUSP5 and thyroid gland carcinoma.